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KEY POINTS
 Interferons (IFNs) have various immunomodulatory functions that are likely conducive to the treat-
ment of cutaneous T-cell lymphoma (CTCL).
 IFN alfa and IFN gamma are the 2 types of IFNs that have primarily been used in the treatment of
CTCL.
 IFNs can cause various laboratory abnormalities and side effects that do not typically necessitate
cessation of therapy, but do require close monitoring on the part of the prescribing physician.
 Although there is a problematic lack of randomized controlled trials assessing the use of IFNs in
CTCL, many studies have argued their efficacy in patients with various stages of CTCL.INTRODUCTION
IFNs are polypeptides produced by stimulated eu-
karyotic cells and naturally occur in the human
body as a part of the innate immune response.1
Although IFNs were originally named in 1957 as a
result of their ability to interferewith viral replication,2
they have since been shown to also have cytostatic
and immunomodulating functions.3 Recognizing the
potential for such functions to combat disease, re-
searchers have used recombinant DNA technology
to produce 3 major types of IFNs, which are
commercially available products approved by the
USFoodandDrugAdministration (FDA) in theUnited
States. These products include IFN alfa, IFN beta,
and IFN gamma. Although subsequent sections of
this article focus almost entirely on the properties
of the IFNs most commonly used in patients with
CTCL, it first examines some of the basic attributes
of the naturally occurring IFN counterparts.Author Conflicts of Interest: None.
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mor cells stimulate leukocytes and lymphoblastoid
cells to produce IFN alfa,4 while T-cell mitogens,
interleukin (IL)-2, and other antigens stimulate T
cells and natural killer (NK) cells to make IFN
gamma.5 Viruses and foreign nucleic acids stimu-
late fibroblasts and epithelial cells to produce IFN
beta.4 As both are stable at the acidic pH of 2
and they bind to the same IFN surface receptors,
IFN alfa and IFN beta are designated as type I
IFNs.5,6 In contrast, because IFN gamma is not sta-
ble at such an acidic pH and binds to a different IFN
surface receptor, it is considered a type II IFN.3
As alluded to above, IFNs have demonstrated
antiviral, cytostatic, and immunomodulatory func-
tions. IFN seems to exert its antiviral impact via
the stimulation of enzymes, which then induce
the cleavage of viral RNA, the inhibition of protein
synthesis, and the production of antiviral proteins.7f Pennsylvania, 3600 Spruce Street, Philadelphia, PA
erelman Center for Advanced Medicine, 3400 Civic
19104.
ublished by Elsevier Inc. This is an open access article
org/licenses/by-nc-nd/4.0/).
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Spaccarelli & Rook732IFNs are cytostatic by their direct inhibition of cell
cycle progression through the S phase8 and
possibly by stimulating enzymes that block protein
synthesis.9,10 The immunomodulatory functions of
IFN alfa and IFN gamma therapies are discussed in
detail in theMechanism of Action sections. As liter-
ature has rarely addressed the use of therapeutic
IFNbeta inCTCL, the authors only discuss it briefly.
INTERFERON ALFA
Although alfa-type IFNs are primarily prescribed for
the treatment of hepatitis C, the National Compre-
hensive Cancer Network guidelines have long
included IFN alfa in its recommended treatments
for the most common types of CTCL, mycosis fun-
goides (MF) and Sezary syndrome (SS).11 Multiple
studies have examined the use of commercially
available IFN alfa in patients with all stages of MF/
SS. Most studies assessing the efficacy of alfa-
type IFNs in the management of MF/SS have
considered 2 forms of recombinant IFN alfa, IFN
alfa-2a (Roferon) and IFN alfa-2b (Intron-A), which
areproducedviagenetically engineeredEscherichia
coli-containing DNA that codes for human pro-
tein.10,12 Roferon is no longer manufactured in the
United States. IFN alfa-2a and IFN alfa-2b share
nearly identical structures because they only differ
in theirmanners of purificationandbya single amino
acid3. These differences do not appear to impact
their antigenicity as both of these IFNs seem to
bind to an identical type I IFN receptor.
The pegylated forms of IFN alfa-2a and IFN alfa-
2b are called Pegasys and PegIntron, respectively,
and are larger in size than their nonpegylated coun-
terparts.14 Despite the lack of large studies or clin-
ical trials assessing these pegylated IFNs in CTCL,
the use of pegylated IFN alfa-2b for this indication
has been reported, so the authors discuss it
when possible. Other commercially available IFN
alfa’s (ie, IFN alfa-n3 and IFN alfacon-1), have not
been used in the treatment of MF/SS12,13 and are
not discussed in this article.
Mechanism of Action
Although IFN alfa has cytostatic and antiviral prop-
erties likeother IFNs, its immunomodulatory effects
seem to beparticularly conducive to combating the
immune dysfunctions observed in CTCL. To pro-
vide a better foundation for understanding the
properties that appear tomake IFN alfa an effective
therapy for MF/SS, it is helpful to first discuss the
proposed mechanisms of immune dysregulation
in these cancers.
The malignant T cells in MF/SS are typically
mature skin-honing memory CD41 helper T cells,
which exhibit a T-helper type 2 (TH2) phenotype intheir release of elevated amounts of IL-4, IL-5,
and IL-10 cytokines.15–17 This increased TH2 activ-
ity seems to create a cytokine imbalance that
suppresses the host’s TH1-mediated immune ac-
tivity18; this is consistent with research showing
that factors produced by TH2 cells counter TH1 ac-
tivity.19,20 Studies have argued that decreased pro-
duction of IFN gamma,15 IL-12, and IFN alfa15,21,22
provide evidence of decreased TH1 activity in pa-
tients with MF/SS and that some of these immune
abnormalities may underlie both the decreased ac-
tivity andnumbers of dendritic cells (DCs) observed
in MF/SS.22 In addition to diminished TH1 immune
activity and DC numbers and activity, other pro-
posed mechanisms of deficient immune activity in
MF/SS include decreased numbers and activities
of both NK cells and CD81 T cells.23,24 These im-
mune defects could bemeans by which the cancer
compromises the host immune system’s abilities to
not only combat infection but also mount an effec-
tive antitumor response.25 Although not neces-
sarily a marker of immune deficiency, peripheral
eosinophilia and elevated serum immunoglobulin
E levels are other immune abnormalities observed
in MF/SS.15,26 In addition to portending a worse
prognosis in MF/SS,27 peripheral eosinophilia in
general has been associated with adverse
events.28
IFN alfa seems to ameliorate several of the im-
mune defects described above. Specifically, IFN
alfa appears to activate CD81 T cells and NK
cells23 and to suppress the problematic increase
in TH2 activity by inhibiting Se´zary cell and normal
T-cell production of IL-4 and IL-5.29–33 IFN alfa
may further augment cytotoxicity by increasing
the expression of class I molecules on lympho-
cytes.34 In addition, culturing the peripheral blood
of patients with SS with recombinant IFN alfa was
observed to significantly inhibit the excess produc-
tion of IL-5, a cytokine that stimulates the prolifer-
ation of eosinophils.31 As noted above, peripheral
eosinophilia has been associated with worse prog-
nosis and adverse events. Fig. 1 adapted from Kim
and colleagues25 summarizes these proposed tar-
gets of IFN alfa therapy in MF/SS.
It is worth mentioning in this section that some
investigators have reported the development of
resistance to IFN alfa.35,36 Downregulation of IFN
receptors,37 production of neutralizing anti-
bodies,10,38 and loss of STAT1 expression in the
malignant T cell39 are purported mechanisms of
resistance.40Pharmacokinetics
IFN alfa is typically administered as a subcutane-
ous (SC) injection in patients with CTCL.
Fig. 1. Pathologic immune abnormalities in CTCL that
likely serve as targets of IFN therapy. CCR4, chemokine
(C-C Motif) receptor 4; CLA, cutaneous lymphocyte-
associated antigen. (Adapted from Kim EJ, Hess S,
Richardson SK, et al. Immunopathogenesis and ther-
apy of cutaneous T cell lymphoma. J Clin Invest
2005;115(4):804; with permission.)
The Use of Interferons in the Treatment of CTCL 733Nonpegylated IFN alfa administered through intra-
muscular (IM) or SC injections reaches peak serum
concentration within 2 to 6 hours.6 The elimination
half-life of nonpegylated IFN alfa-2b is 2 to 3 hours
and that of nonpegylated IFN alfa-2a is slightly
longer. The pegylated forms of IFN alfa have
much longer elimination half-lives than their nonpe-
gylated counterparts. This prolonged half-life is
because the addition of polyethylene glycol to their
structures makes them more resistant to break-
down by proteolytic enzymes than the nonpegy-
lated forms. The elimination half-life of pegylated
IFN alfa-2a is approximately 80 hours, whereas
that of pegylated IFN alfa-2b is approximately
40 hours.3,40 In addition, pegylated IFN alpha-2b
acts primarily as a prodrug with its slow IFN
release.14
IFN alfa is metabolized by the liver, filtered
through the glomeruli, and undergoes degradation
during tubular resorption.12 IFN alfa has also been
administered intralesionally in MF. Although this
method is safe, the systemic absorption of the
IFN may be decreased.41,42
Typical Dosing
The following discussion focusesmostly on nonpe-
gylated IFN alfa dosing and is gleaned from
research on both IFN alfa-2a and IFN alfa-2b with
the underlying assumption that because these
types of IFN alfa are nearly biologically identical,
they should behave almost equivalently. However,
such an assumption is likely imperfect because
some differences do exist between the 2
compounds.3
There is a wide range of doses reported in litera-
ture examining the use of IFN alfa in MF or SS. Themaximally tolerated dose of nonpegylated IFN alfa
has been reported to be 9 to 18 million units (MU)
daily, but most clinicians seem to treat patients
with 3 to 6 MU thrice weekly or daily.35,43–45 It has
been suggested that patients who are initially
administered lower doses before being escalated
to higher doses tolerate the higher doses better
than individuals who are initially administered
higher doses.46 As discussed earlier, IFN alfa may
also be administered intralesionally. If only aiming
to treat the injected plaque or tumor, injecting 1
to 2 MU into the lesion 3 times a week until signifi-
cant improvement is observed is reasonable.41,42
There is some suggestion that higher doses of
IFN alfa, if tolerated, are more effective than lower
doses.35,47,48 Several patients in the study by
Olsen and colleagues,35 which randomized pa-
tients to 36 MU versus 3 MU per day, were able to
achieve complete remission only after their dose
was increased or the higher dose was continued
for longer than the 10-week induction period.
Unlike nonpegylated IFN alfa, which is generally
given as fixed doses unrelated to patient weight,
pegylated IFN alfa-2b should be dosed according
to the formula 1.5 mg/kg/wk. However, at the au-
thors’ center at the Hospital of the University of
Pennsylvania, patients are typically initially admin-
istered approximately half of this dose and then
the dose is eventually increased to 1.5 mg/kg/wk
as tolerated. In contrast to the variable frequency
of nonpegylated IFN alfa, pegylated IFN alfa-2b
or IFN alfa-2a is given as a once-weekly injection
because of its extended half-life.49
The lack of large-scale randomized controlled
trials assessing IFN alfa in MF/SS has meant that
its precise use, particularly in regard to duration
of therapy, is highly institution dependent. For
example, Elise Olsen of Duke University’s Depart-
ment of Dermatology has described her typical
regimen as the following. Nonpegylated IFN alfa
is usually started at 3 MU thrice weekly; half the
dose is administered in elderly or debilitated pa-
tients for the first 2 weeks. Response is assessed
at 3 months, and if at that time there is minimal
to no response, then either the IFN is escalated
to 3 MU daily or a retinoid is added. If the patient
attains a complete response (CR), Olsen recom-
mends continuing that dose for at least 3 months
thereafter and then slowly reducing the dose or
frequency over the following 6 to 12 months in
the absence of relapse.3 Although there is some
evidence that the efficacy of IFN alfa could persist
in patients who attain partial responses (PRs) on
higher doses and are then administered lower
doses for maintenance,44,46 others contend that
objective response (OR) could be compromised
by a premature dose reduction before attaining a
Spaccarelli & Rook734CR.35 If using pegylated IFN, because of the un-
availability of multidose vials, Olsen either begins
at 50 or 80 mg of pegylated alfa-2b (PegIntron)
weekly taking into account the weight, age, and
physical condition of the patient, escalating to
120 or 180 mg weekly, or instead uses 90 mg of pe-
gylated IFN alfa-2a (Pegasys) weekly escalating to
the higher dose vials of 135 or 180 mg weekly as
tolerated—there is no preference for either pegy-
lated forms, but one or the other may be preferred
by a patient’s insurance carrier.
In slight contrast to the approach described
above, the authors’ practice typically involves
starting nonpegylated IFN alfa-2b, 1.5 MU thrice
weekly, and then escalating the dose as tolerated
to 3 MU thrice weekly. If the patient does not
improve at such a dose after 3 months of therapy,
the authors typically increase the frequency to 4
timesweekly or increase the dose up to 5MU. After
3 to 4 months without improvement on such a
regimen, the authors add other therapies before
altering the therapeutic approach. If using pegy-
lated IFN alfa-2b, the authors administer 0.75 to
1.5 mg/kg/wk. However, if the patient does not
show improvement after 3 to 4months, the authors
do not escalate the dose. Instead, they add an
additional therapy and may either stop or continue
the pegylated IFN alfa-2b.
Although a lack of clear recommendations
regarding duration of therapy is frustrating, a
benefit of IFN alfa therapy over many other sys-
temic treatments for MF or SS is that it is not asso-
ciated with chronic cumulative dose effects or
secondary malignancies such that its long-term
use seems safe in most patients.3 However, there
is a small risk of new or exacerbated autoimmune
disease during long-term therapy (see sections
Adverse Effects).
Response to Therapy
While there are many prospective studies and
retrospective case series evaluating IFN alfa in
MF/SS, there are few randomized controlled trials.
Despite this, it is widely accepted that IFN alfa can
be effective in all stages of MF or SS.3 In this sec-
tion, some of the largest published studies of IFN
alfa in patients with MF/SS are detailed. Readers
may refer to Table 1 for a synopsis of published
studies that assess IFN alfa in 20 or more subjects
with MF or SS.
Interferon alfa alone
In 1984, Bunn and colleagues13 first argued the ef-
ficacy of IFN alfa in CTCL. In this prospective trial,
20 patients with what was described as advanced-
stage disease (5 with stage II, 2 with stage III, and
13 with stage IV MF using the TNM stagingsystem) were initially given significant doses (50
MU) of IFN alfa-2a thrice weekly and with dose
reduction if side effects were intolerable. Of the
20 patients, 9 patients (45%) experienced a PR
with a median response duration of 5 months.
No patient experienced a CR. Not surprisingly, all
patients required dose reductions to at least
50% of the initial dose because of intolerance. In
response to the demonstrated difficulty in toler-
ating such high doses of IFN alfa, a subsequent
1990 trial by Kohn and colleagues50 attempted to
use pulse doses of recombinant IFN alfa-2a. Pa-
tients were given 10 MU on day 1 followed by 50
MU on days 2 to 5 every 3 weeks. Of the 24 sub-
jects enrolled in this trial, 1 patient had a CR and
6 subjects had PRs; this resulted in a 29% OR
rate, and the median response duration was
8 months. Readers may refer to Table 1 for study
details. Since the study by Kohn and colleagues,50
clinical trials have typically dosed IFN alfa 1 to 3
times weekly, not in a pulsed manner.
Papa and colleagues45 prospectively analyzed
43 patients with stage I to IVB CTCL who received
between 3 and 18 MU IFN alfa-2a (whatever dose
each subject maximally tolerated) thrice weekly for
3 months, and responders were then continued on
their maximally tolerated doses for 6 months. This
study showed an impressive OR in 70% of pa-
tients with stage III or IV disease and in 80% of
those at lesser stages. Among this study’s sub-
jects were 28 newly diagnosed and previously
untreated patients. Not surprisingly, the study re-
ported a greater overall response rate in the previ-
ously untreated subjects. However, the difference
was not marked (79% or 22 of 28 previously un-
treated subjects vs 67% or 10 of 15 previously
treated subjects). These findings complement
those of the multicenter controlled trial by Olsen
and colleagues,35 which included patients with
stage IA to IVA disease treated with IFN alfa-2a,
3 MU daily (n58) or 36 MU daily (n514). At the
end of 10 weeks, all on the higher dose required
a dose reduction, including decrease in dose in
6 of 14 patients to 3 to 3.6 MU/d; 10 patients
(45.5%) had a PR (including 3 patients with stage
IIB MF), 3 patients (13.6%) achieved a CR, 2 of
which had stage IVA disease. An additional 3 pa-
tients achieved a CR with longer treatment times
(27% overall) with a duration of CR in these 6
patients of 4 to 27.5 months. Overall response
was greater in those receiving higher doses.
Another prospective trial by Tura and colleagues46
found that all 15 of its subjects (stage II–IV) expe-
rienced some reduction in skin lesions (3 CR, 9
PR, and 1 mild response) in response to IFN
alfa-2a with a dosing protocol dispensing 3 to 18
MU daily for 3 months followed by 18 MU thrice
Table 1
Studies of at least 20 subjects assessing IFN alfa both alone and in combination with other treatments
Study, Year Design Treatmenta
Number of Subjects,
Stage Range of Subjects Key Results
Bunn
et al,13 1984
Prospective
observational
IFN alfa-2a 20, stage II–IVB 9/20 (45%) achieved PR, 0/20 (0%) achieved CR, responses did
not correlate with stage, extremely high (50 MU/wk) doses of
IFN used, all subjects required dose reduction
Olsen
et al,35 1989
Prospective
observational
IFN alfa-2a 22, IA–IVA 3/22 (14%) achieved CR and 10/22 (45%) achieved PR after 10wk,
2 patients with PR and 1 patient with stable response then
went into CR with further treatment, remissions lasted 4–
27.5 mo, response was greater at higher doses than at lower
dose
Kohn
et al,50 1990
Prospective
observational
IFN alfa-2a 24, IA–IVB 1/24 (4%) achieved CR, 6/24 (25%) achieved PR, no improvement
seen in 8 patients who received dose escalation
Papa
et al,45 1991
Prospective
observational
IFN alfa-2a 43, I–IVB 11/43 (26%) achieved CR, 21/43 (49%) achieved PR, greater
response in previously untreated subjects
Stadler
et al,56 1998
Randomized
clinical trial
IFN alfa-2a with
PUVA vs IFN alfa-2a
with acitretin
98 randomized, 82
evaluable, stage IA–IIB
28/48 (70%) patients receiving IFN and PUVA achieved CR (26/31
stage I, 2/9 stage II), 16/42 (38%) receiving IFN and acitretin
achieved CR (16/33 stage I, 0/9 stage II), median time to CR
much shorter in IFN and PUVA group (18.6 wk) than IFN and
acitretin group (21.8 wk)
Jumbou
et al,51 1999
Retrospective
observational
IFN alfa-2a 51, IA–IV 21/51 (41%) achieved CR (5/8 stage I, 1/1 stage IIA, 13/30 stage
IIB, 2/11 stage III, 0/1 stage IV), 13/51 (25%) achieved PR (2/8
stage I, 0/1 stage IIA, 10/30 stage IIB, 1/11 stage III, 0/1 stage IV),
mean time to CR was 4 mo and independent of stage
Kuzel
et al,36 1995
Prospective
observational
PUVA with IFN alfa-2a 39, IB–IVB 24/39 (62%) achieved CR, 11/39 (28%) achieved PR, median
response duration was 28 mo
Chiarion-Sileni
et al,57 2002
Prospective
observational
PUVA with IFN alfa-2a 63, IA–IVA 51/63 (75%) achieved CR, 6/63 (10%) achieved PR, median
response duration was 32 mo
Rupoli et al,59
2005
Prospective
observational
PUVA with IFN alfa-2b 89, IA–IIA 75/89 (84%) of subjects achieved CR (82% of stage IA, 87% of
stage IB, 73% of stage IIA), median time to CR was 6 mo
Nikolaou
et al,58 2011
Retrospective
observational
PUVA with IFN alfa-2b 22, IB–IVA 10/22 (45%) achieved CR, 5/22 (23%) achieved PR, more subjects
in early stages (stage IA-IIA) achieved CR than those in later
stage (IIB–IV) (96% vs 27%, P value .03)
(continued on next page)
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Table 1
(continued )
Study, Year Design Treatmenta
Number of Subjects,
Stage Range of Subjects Key Results
Wozniak
et al,60 2009
Randomized
clinical trial
PUVA vs PUVA with
IFN alfa
29, IA–IIA 13/17 (76%) subjects on PUVA alone achieved CR, 9/12 (75%)
on PUVA and IFN achieved CR, none of the 29 patients
achieved PR
Hu¨sken
et al,62 2012
Retrospective
observational
PUVA with pegylated
IFN alfa-2a vs PUVA
with nonpegylated
alfa-2b
17, IA–IV 4/9 (44%) achieved CR and 4/9 (44%) achieved PR in PUVA with
pegylated IFN alfa-2b group, 3/8 (38%) achieved CR and 1/8
(13%) achieved PR in PUVAwith IFN alfa-2a group, higher rate
of myelosuppression and liver toxicity and lower rate of
constitutional side effects in pegylated combination group
Wagner
et al,76 2013
Retrospective
observational
TSEBT alone vs TSEBT
with IFN alfa-2b
41, IA–IVA 63% of subjects on combination achieved CR and 36% of
subjects on TSEBT alone achieved CR but this difference was
not statistically significant, no difference in overall survival
and progression-free survival detected between the 2 groups
CR is the complete clearance of all skin lesions lasting at least 4 weeks and PR is at least 50% reduction of skin lesions lasting at least 4 weeks; wk ,weeks; mos, months.
Abbreviations: PUVA, psoralen plus ultraviolet A; TSEBT, total skin electron beam therapy.
a IFN administered is nonpegylated unless otherwise noted.
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The Use of Interferons in the Treatment of CTCL 737weekly for 6 months. However, this study also
found that many patients could not tolerate 18
MU daily and suggested that future trials not give
subjects older than 60 years doses greater than
9 MU/day.
A larger-scale retrospective study by Jumbou
and colleagues51 looked at 51 subjects with stage
IA to IV CTCL who used IFN alfa-2a monotherapy
at a mean dose of 2.7 MU daily for a mean duration
of 15.8 months. The investigators reported 21 sub-
jects with CRs, 13 with PRs, and 17 with stable or
progressive disease. Although CRs were more
common in lower stages, time to CR and the dura-
tion for which the CR was sustained were actually
independent of stage. CRs were obtained within
6 months and lasted an average of 31 months.
Readers may refer to Table 1 for further study
details.
There are numerous smaller-scale studies as-
sessing the use of IFN alfa monotherapy in CTCL.
Although Estrach and colleagues,52 Dallot and col-
leagues,53 and Vonderheid and colleagues41
demonstrated good responses to IFN alfa-2b
among patients with MF/SS, the positive results
in Vonderheid and colleagues’41 study were limited
to the improvement of specific plaqueswith intrale-
sional injections because the study patients did not
seem to improve with subsequent IM injections of
IFN alfa-2b. Other small-scale studies have re-
ported responses in patients with MF/SS of all
stages to IFN alfa-2a monotherapy.43,44,54
Interferon alfa in combination with psoralen
plus ultraviolet light phototherapy
Several studies have examined the use of concom-
itant IFN alfa and psoralen plus ultraviolet A (PUVA)
phototherapy. Kuzel and colleagues36 and Stadler
and Otte55 argued in their 1995 trials of 39 and 16
subjects, respectively, that the CR rates they
demonstrated with the combination of IFN alfa-2a
and PUVA were superior to those demonstrated
in previous studies with IFN or PUVA alone. While
neither study compared the combination treatment
groups directly tomonotherapy groups, a later pro-
spective randomized study of 98 subjects with
stage IA to IIB disease by Stadler and colleagues56
compared the efficacy of IFN alfa-2a (9 MU thrice
weekly) and PUVA (5 times weekly during first
4 weeks, 3 times weekly during weeks 5 through
23, 2 times weekly during weeks 24 through 48)
with that of IFN alfa-2a (9 MU thrice weekly) and
acitretin (25 mg daily during week 1, 50 mg during
weeks 2 through 48). The combination of PUVA
and IFN resulted in CR in 70%of subjects, whereas
only 38.1% of subjects in the IFN and acitretin
group experienced CR. Table 1 provides further
study details. A later study by Chiarion-Sileni andcolleagues57 found an impressive CR rate of 75%
(mean response duration of 37 months) in 63 pa-
tients with stage IA to IVA disease treated with
PUVA and IFN alfa-2a, but did not directly compare
these results with those of subjects undergoing
monotherapy. However, CRs were obtained in all
stages of disease. Like Chiarion-Sileni and
colleagues,57 a case series by Nikolaou and col-
leagues58 showed an impressive overall response
rate of 68%. In a phase 2 prospective trial of 89 pa-
tients with stage IA to IIA CTCL by Rupoli and col-
leagues59 reported an impressive overall response
rate of 98% for IFN (6–18 MU weekly) and PUVA
but it did not compare these results to those of pa-
tients treated with monotherapy. Table 1 provides
details of the studies by Chiarion-Sileni and col-
leagues,57 Nikolaou and colleagues58 and Rupoli
and colleagues.59
In contrast to the results of Rupoli and col-
leagues’59 study, Wozniak and colleagues60 did
not demonstrate significant differences in
response to PUVA alone versus PUVA and IFN
alfa in their randomized controlled trial of 29 pa-
tients with similar low-stage disease (IA–IIA).
Humme and colleagues61 conducted an overall
assessment of the many trials looking at the com-
bination of IFN alfa and PUVA including that by
Wozniak and colleagues.60 This review pooled
the results of 11 selected trials that investigated
the combination of PUVA and IFN alfa, including
3 randomized controlled trials, 3 prospective
cohort studies, 2 retrospective case series, 2 unde-
fined trials, and a study that included data from a
retrospective analysis as well as a prospective ran-
domized trial. Although this review calculated a
mean overall response rate of 79%  15% across
all trials, it concluded that the addition of IFN alfa
did not increase the efficacy of PUVA in patch- or
plaque-stage MF. The study did not address
whether the time to response was decreased or
unchanged with the addition of IFN to PUVA.
Although there is little mention of the use of pe-
gylated IFN alfa in CTCL, a retrospective cohort
study by Hu¨sken and colleagues62 compared 9 pa-
tients with stages IA to IV CTCL (2 stage IA, 3 stage
IB, 2 stage IIA/B, 1 stage III, 1 stage IV) treated with
PUVA and pegylated IFN alfa-2b (1.5 mg/kgweekly)
to 8 patients (2 stage IA, 4 stage IB, 1 stage IIA/B,
and 1 stage III) treated with PUVA and nonpegy-
lated IFN alfa-2a (9 MU thrice weekly). While this
study concluded that myelosuppression and liver
toxicity occurred more frequently in the pegylated
group, it also found that overall response was
much higher in the pegylated group than in the non-
pegylated group (89% vs 50%). However, like
many of the studies described above, its conclu-
sions are limited by its small size.
Spaccarelli & Rook738Interferon alfa in combination with oral
retinoids
Several small studies have suggested that oral ret-
inoids and IFN alfa aremore effective together than
as monotherapy in the treatment of MF/SS. Straus
and colleagues63 conducted a prospective trial in
which 22 patients with stage IB to IV disease were
first treated with oral bexarotene (300 mg/m2/d for
8 weeks), and then those who had not improved
on bexarotene alone were given IFN alfa-2b (3–5
MU thrice weekly) in addition to bexarotene. Of
the 8 of 22 subjectswho had not responded to bex-
arotene alone and were given IFN alfa-2b, there
was a 38% overall response rate (3/8) after the
IFN alfa-2b was added. Other literature has sug-
gested that combinations of IFNalfa-2bwith bexar-
otene,64 isotretinoin,65 or etretinate44,66 are
effective, but such studies are limited by their small
size and their failure to directly compare their re-
sults to those of monotherapy.
Interferon alfa in combination with
extracorporeal photopheresis
Multiple small-scale studies have attempted to
determine the efficacy of IFN alfa and extracorpo-
real photopheresis (ECP). One of the larger
analyses was by Dippel and colleagues67 who
retrospectively compared the responses of 9 pa-
tients who received both ECP and IFN alfa-2a (3–
18 MU thrice weekly) with those of 10 patients
who received ECP alone and found a better
response rate in the subjects on combination ther-
apy. A prospective controlled study byWollina and
colleagues68 assessed the use of twice-monthly
ECP and IFN alfa-2a (6–18 MU thrice weekly) in
14 patients with stage IIA and IIB CTCL. After
6months, 60%patientswith stage IIA and 25%pa-
tients with stage IIB CTCL had some response
(either CR or PR) to therapy. Although other case
reports also promote the efficacy of IFN alfa in
combination with ECP,69–71 a pilot study by Von-
derheid and colleagues72 of 6 patients with SS
did not find a significant response to treatment
with ECP and IFN alfa-2b. Similarly, the only pro-
spective study in patients with various stages of
MF/SS comparing IFN alfa alone to the combina-
tion of IFN alfa and ECP failed to show an improved
response of the combination regimen over IFN
alone.10 This finding is echoed by Humme and col-
leagues61 who compared the findings of Wollina
and colleagues68 with those of trials assessing
IFN alfamonotherapy and concluded that the com-
bination of IFN alfa and ECP are not superior to IFN
alone. This observation has raised the question as
articulated by Zackheim and colleagues73 of
whether there is genuinely an additive or synergis-
tic effect with the combination of ECP and IFN alfaand underscores the necessity of a prospective
randomized clinical trial to address this.40 Never-
theless, at the authors’ center, patients with SS
are routinely treated with IFN alfa and ECP, and
this approach is found to be effective.74
Interferon alfa in combination with total skin
electron beam therapy
Although there aremany published examples of to-
tal skin electron beam therapy (TSEBT) being used
in conjunction with IFN therapy,74 the evidence
supporting the notion that the combination of the
2 therapies is more effective than either treatment
alone is lacking. A study by Roberge and col-
leagues75 compared the outcomes of 31 patients
with various stages of MF treated with TSEBT
alone with those of 19 patients with various stages
of MF treated with both TSEBT and IFN alfa. In
those 19 subjects, IFNwas given both concurrently
with TSEBT and after the completion of the entire
course of TSEBT. This study concluded that there
was not a significant difference in CR, disease-
free survival, or overall survival between the 2
groups (median follow-up for living patients was
70 months). Similarly, a later retrospective study
by Wagner and colleagues76 assessed 41 patients
who received TSEBT either alone or in combination
with IFN alfa-2b and found CRs in 63% of patients
receiving the combination regimen versus in 35%
of patients receiving TSEBT alone. However, this
difference was not statistically significant and the
study did not show a statistically significant differ-
ence in overall survival or progression-free survival
between the combination and monotherapy
groups. Despite such a lack of published evidence,
the authors’ center feels justified in concomitantly
treating patients with both TSEBT and IFN given
the ability of electron beam radiation to induce
apoptosis in malignant T cells77 and the probable
ability of IFNs to enhance the immune system’s
processing of apoptosed cells.
Interferon alfa in combination with
chemotherapeutics
The use of IFN alfa in conjunction with chemother-
apeutics is not common. Studies by Foss and col-
leagues78,79 showed an objective response in only
41% of patients with stage I to IVB MF/SS treated
with pentostatin (4 mg/m2 on days 1 through 3
every 42 days) and IFN alfa-2a (10 MU/m2 on day
22 and 50 MU/m2 on days 23 through 26) and in
51% of patients with stage I to IVB MF/SS treated
with fludarabine (25/m2 on days 1 through 5 every
28 days) and IFN alfa-2a (5–7.5 MU/m2 SC thrice
weekly). In marked contrast, the study by Avile´s
and colleagues80 reported an impressive CR in
74% of 158 patients with stage IIB to IVA CTCL
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biweekly) and IFN alfa-2b (9 MU thrice weekly).
The investigators did not provide a mean duration
of response, but the 10-year estimated survival
was 69%. It seems that a possible mechanism for
this efficacy could be that MTX and IFN together
enhance the expression of Fas (CD95), which aug-
ments Fas/Fas ligand-induced apoptosis of the
malignant T-cell population.81 However, the
shortage of reported adverse effects in Aviles and
colleagues study was unusual considering the tox-
icities usually associated with both MTX and IFN
alfa monotherapy.40
Interferon alfa as part of multimodality
treatment
It is perhaps most difficult to assess the efficacy of
IFN alfa as part of multimodality treatment, which
the authors define as 3 or more systemic CTCL
agents given concurrently. In addition to IFN alfa,
agents most often included in multimodality treat-
ment include PUVA, oral retinoids, and ECP.
Although there are reports of successful responses
to the combinations of vorinostat/IFN alfa-2a/
ECP,82 IFN alfa-2a/ECP/PUVA,83 and IFN alfa/
ECP/IL-284 and retrospective cohort analyses
that promote the multimodality approach,75,85
none of the available literature includes trials that
directly compare multimodality regimens to either
each other or to regimens consisting of 1 to 2 treat-
ments. Nevertheless, the authors’ center routinely
treats more advanced stages of CTCL with multi-
modality regimens that most often include IFN, an
oral retinoid, skin-directed therapy, and/or ECP.Adverse Effects
The most common acute side effects of IFN alfa
are described as flulike and include fever, fatigue,
chills, myalgias, arthralgias, and headache. Pa-
tients most frequently experience these symptoms
during the hours immediately after the IFN injec-
tion and usually only during the first 2 weeks of
treatment. Taking acetaminophen before the IFN
injection can mitigate these discomforts. The
most common chronic side effects of IFN alfa
include fatigue, appetite loss, and weight loss
(usually 2.3–4.5 kg).3 These common side effects
generally are dose related, decline in severity
over time, and do not usually require dose reduc-
tion or cessation of therapy. Dose-related cytope-
nias (most commonly anemia, thrombocytopenia,
and leukopenia) are relatively frequent side effects
that may require dose reduction or stoppage of
therapy if severe.40 However, in the absence of
prior chemotherapy or known primary immuno-
suppressive disorder, the authors’ center usuallydoes not alter dose when neutrophil counts are
above 500 per mm.
While other possible side effects of IFN alfa are
less common than those mentioned above, they
are nonetheless worth discussing because they
can become dangerous if they go unrecognized
and may require dose reduction or cessation of
therapy. Depressedmood and increased irritability
have been reported with IFN alfa, and physicians
should proceedwith caution particularly in patients
with a history of mood disorders. Impaired cogni-
tive function is also possible and is usually more
marked in the elderly. Thyroid dysfunction (most
often hypothyroidism, but thyroiditis has been
notedaswell) canoccur inup to20%ofpatients us-
ing IFN alfa. Prescribing physicians should have a
low threshold to draw thyroid function blood tests
in patients with worsening fatigue despite being
on a stable IFN dose. Altered taste, diarrhea, and
elevated values of liver function tests may also
occur but are usually mild and do not typically
require dose modification. Peripheral neuropathy
has been reported and, if severe, may require
dose reduction or stoppage of therapy. Visual and
auditory impairments, including the development
of retinal cotton wool spots, are rare side effects,
but such patients should immediately be referred
to the appropriate specializing physicians to best
assess the cause of the visual or auditory dysfunc-
tion. If IFN is deemed the likely culprit of visual or
auditory impairment, the drug is usually stopped.40
There have also been reported cases of IFN alfa
both inducing and worsening autoimmune disor-
ders.86 As a result, prescribers may be hesitant
to use IFN alfa in patients with known autoimmune
disease. In addition, IFN alfa is thought to possibly
have antiangiogenic properties87 such that the au-
thors’ center routinely stops IFN for 1 week before
scheduled surgery and does not restart IFN until
1 week after surgery. Since IFN alfa was first intro-
duced, various forms of cardiac toxicity have been
reported and have included cardiac arrhythmias,
cardiomyopathy, myocarditis, and myocardial
infarction. However, some research has argued
against the association of IFN alfa with these car-
diac toxicities.88 In addition, it seems that these
events occurred at higher doses of IFN alfa than
those generally used in the treatment of MF or
SS. Nonetheless, patients with a history of coro-
nary artery disease should be carefully monitored
while on IFN.40
Although the list of possible side effects of IFN
alfa is long, the vast majority of these adverse
events seem reversible once IFN alfa is stopped.
That there seem to be no long-range cumulative
dose effects in most patients likely makes the
drug safe for long-term use if tolerated.40
Spaccarelli & Rook740INTERFERON GAMMA
In contrast to the use of recombinant IFN alfa, there
is much less literature regarding the use of IFN
gamma in systemic diseases. IFN gamma-1b (Ac-
timmune) is the only commercially available re-
combinant form of IFN gamma and is approved
by the FDA for the treatment of chronic granuloma-
tous disease and osteoporosis.3 Although there is
a lack of large-scale cohort studies and trials eval-
uating the use of IFN gamma in patients with CTCL,
there are some reports of its utility for this indica-
tion. Because there is little literature addressing
IFN gamma in MF or SS, the authors’ examination
of the use of IFN gamma in these conditions is
limited. Nevertheless, the authors’ program has
administered IFN gamma to more than 200 pa-
tients with MF or SS during the past 20 years and
has found it to be a promising modality.
Mechanism of Action
IFN gamma has many important functions in both
the innate and adaptive immune responses
including, but not limited to, the stimulation of
DCs and macrophages to upregulate major histo-
compatibility complexes leading to enhanced anti-
gen presentation, activation of NK cells, and
increasing expression of costimulatory molecules.
In addition, IFN gamma is considered essential for
the TH1 immune response.
89 Researchers have
postulated that many of these functions could un-
derlie the utility of IFN gamma in MF/SS. Specif-
ically, enhancement of cytotoxicity mediated by
CD81 T cells and NK cells, priming of DCs, inhibi-
tion of tumor cell proliferation, reduced TH2 im-
mune activity, increased TH1 immune activity,
and inhibition of T regulatory cells are proposed
mechanisms of IFN gamma’s efficacy in MF/SS.40
Pharmacokinetics and Dosing
Like recombinant IFN alfa, recombinant IFN
gamma-1b is most often administered as an SC in-
jection in patients with MF/SS; it has also been
given intralesionally but less commonly than IFN
alfa in patients with MF/SS. The recommended
dosage is 50 mg/m2 (1 MU/m2) for patients whose
body surface area is greater than 0.5 m2 and
1.5 mg/kg/dose for patients whose body surface
area is equal to or less than 0.5 m2. The mean elim-
ination half-lives of IM and SC doses equivalent to
100 mg/m2 are 2.9 and 5.9 hours, respectively.
Peak plasma concentrations occur 4 hours after
IM dosing and 7 hours after SC dosing.90 IFN
gamma injections seem to be most frequently pre-
scribed as daily to thrice-weekly injection in pa-
tients with MF/SS. At the authors’ center,typically patients are first administered 1 MU thrice
weekly and then the dose is increased as tolerated
to 2 MU thrice weekly.
Response to Therapy
Interferon gamma alone
The first report of using recombinant IFN gamma-
1b in patients with MF/SS was published in 1990.
In this prospective phase 2 study by Kaplan and
colleagues,91 16 patients with MF/SS of various
stages (IB–IVB) received recombinant IFN gamma
for at least 8 weeks. The investigators reported
an objective PR in 31% of patients and noted that
1 of 5 subjects with an objective PR had previously
progressed after an initial PR to IFN alfa-2a.
Although this study offered that IFN gamma may
be effective in patients with MF or SS, its very small
size and lack of control arm limited its ability to
compare such efficacy to the efficacy of other
treatments such as IFN alfa. The authors’ group
has found some success in using recombinant
IFN gamma-1b in patients who have failed to
respond to IFN alfa. Although on a smaller scale
and via a different mechanism of IFN delivery
than used byKaplan and colleagues,91 another trial
in 2004 by Dummer and colleagues92 also as-
sessed the use of IFN gamma alone in subjects
with CTCL. A total of 5 subjects with CTCL in this
phase 1 prospective study received intralesional
injections of IFN gamma complementary DNA con-
tained in an adenoviral vector. The local intrale-
sional injections resulted in impressive
improvement of individual lesions in these patients.
In addition, elevated serum levels of IFN gamma
were observed, which seemed to be associated
with regression of uninjected lesions.25
Themost recent study investigating the use of re-
combinant IFN gamma-1b in patients with MF/SS
waspublished in 2013 bySugaya andcolleagues.93
This prospective phase 2 study administered IFN
gamma-1b (2 MU daily for 5 days each week for
4 weeks followed by intermittent injections) to 15
patients with stage IA to IIIA CTCL. The investiga-
tors reported that 11 of 15 subjects had PRs
including 9 of 10 subjects with stage IA to IIA
CTCL, 1 of 4 subjects with stage IIB CTCL, and 1
of 1 subject with stage IIIA CTCL. There was no CR.
Interferon gamma as part of combination
treatment
Although there are no trials comparing IFN
gamma-1b directly to other CTCL treatments,
several case reports and series have recorded pa-
tients with MF/SS responding to IFN gamma-1b
administered in conjunction with other therapies
such as bexarotene, ECP, TSEBT, and vorino-
stat.74,94,95 A prospective study by Shimauchi
The Use of Interferons in the Treatment of CTCL 741and colleagues96 treated 12 patients with MF (4
with erythroderma and the rest with plaque dis-
ease) with recombinant IFN gamma or natural
IFN gamma for 5 days weekly for 4 weeks in
conjunction with narrowband ultraviolet B
(NBUVB) therapy three times weekly. Of the 12 pa-
tients, 6 had a PR and 4 had a CR. This study also
measured particular TH1 and TH2 cytokine levels in
all 12 subjects who received the combination of
IFN gamma and NBUVB and an additional 3 pa-
tients who received NBUVB alone. It was found
that TH1 chemokine levels were elevated and TH2
chemokine levels were depressed in the combina-
tion group when compared with those receiving
NBUVB alone.
The authors’ center has used IFN gamma exten-
sively as a component of multimodality treatment.
The authors surmise that an advantage of IFN
gamma over IFN alfa could be the former’s ability
to prime and enhance antigen-presenting cell
functions. The authors think this could be particu-
larly advantageous when used in conjunction with
treatments such as ECP, PUVA, or TSEBT, which
induce apoptosis of malignant T cells. Use of the
IFN gamma can presumably enhance the afferent
immune response to the apoptotic tumor cells
leading to a more effective efferent immune
response mediated by cytotoxic T cells.
Although not published in large case series or
studies, the authors’ practice has occasionally
used IFN gamma and IFN alfa (usually not adminis-
tering both on the same day) simultaneously in pa-
tients who have failed to achieve adequate control
on a single IFN and have found that this regimen
can be helpful if tolerated.
Adverse Effects
The adverse effects of IFN gamma-1b are nearly
identical to those of IFN alfa. Side effects are
most often flulike and include low-grade fever, my-
algias, fatigue, and arthralgias. Like IFN alfa, IFN
gamma can also induce nausea, headache, weight
loss, dose-dependent cytopenias, liver function
enzyme abnormalities, nonscarring alopecia, and
the triggering of autoimmune phenomena.91 One
of the advantages cited in using IFN gamma over
IFN alfa is that it does not seem to impair the cogni-
tive or mood functions of elderly patients as often
as IFN alfa.40 The authors’ group has found IFN
gamma to be less frequently associated with auto-
immune side effects and peripheral neuropathy
than IFN alfa.
INTERFERON BETA
Although there are 2 commercially available beta-
type IFNs, IFN beta-1b (Betaseron) and IFN beta-1a (Avonex), they are almost exclusively used in
the treatment of multiple sclerosis so the authors
summarize their attributes in an abbreviated
manner. These IFNs are administered via IM or
SC injections, and their side effect profile is very
similar to that of IFN alfa.12 Although there are no
sizable studies or trials assessing the use of IFN
beta in CTCL, a notable study is that by Zinzani
and colleagues.97 This group analyzed the use of
daily IFN beta injections for 4 months in 5 patients
with treatment-refractory stage III MF and 3 pa-
tients with previously untreated stage I and II MF
and reported only a single OR (12.5%).3TREATMENT PEARLS FOR PRESCRIBING
PHYSICIANS
 It is reasonable to start nonpegylated IFN alfa,
1.5 to 3 MU, thrice weekly and increase the
dose to 5 MU thrice weekly as tolerated. If
the patient does not respond, increasing the
frequency of the tolerated dose is an option,
but the authors typically do not exceed 4
times weekly.
 Many patients experience constitutional side
effects with IFNs, but these usually diminish
over time. Starting at a lower dose and esca-
lating the dose as tolerated and taking acet-
aminophen immediately before injection
likely increase the tolerability of the drug.
 Laboratory abnormalities including cytopenias
and elevated values of liver function tests can
occur with IFNs, so prescribing physicians
should monitor complete metabolic panels
and complete blood cell counts. Mild abnor-
malities are typically tolerated without dose
modification. If moderate or severe abnormal-
ities occur, one should consider dose reduc-
tion or stopping the drug and referral to the
appropriate specializing physician (hematolo-
gist or gastroenterologist) to address whether
IFNs are contraindicated in the patient.
 Although the long-term use of IFNs seems
safe, they should be used with caution in pa-
tients with history of autoimmune, mood,
cognitive, and/or cardiovascular disorders.SUMMARY
Although the available literature demonstrating the
utility of recombinant IFN alfa in the treatment of
CTCL is convincing, more randomized controlled
trials directly comparing it both as a monotherapy
and as part of combination therapy, particularly its
pegylated form, to other systemic modalities used
in CTCL are necessary. In addition, larger-scale
studies evaluating IFN gamma both alone and in
Spaccarelli & Rook742comparison to other systemic CTCL treatments
including IFN alfa would greatly enhance the un-
derstanding of its efficacy in CTCL.REFERENCES
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